Case-based lecture: Immune effector cell associated neurological syndrome: neurotoxicity and long-term symptoms

ESH eLearning, Frederick Locke, 403584

Interactive case: Prediction of toxicity in CARs and bispecifics

ESH eLearning, Anna Sureda, 403582

Access in different ethnic groups

ESH eLearning, Loretta Nastoupil, 403581

Patient survey

ESH eLearning, Natacha Bolanos, 403579

Future projections

ESH eLearning, Frederick Thielen, 403578

Con

ESH eLearning, Jordan Gauthier, 403577

Pro

ESH eLearning, Frederick Locke, 403576

Interactive case: T-cell lymphoma

ESH eLearning, Kate Cwynarski, 403575

Case-based lecture: Follicular lymphoma and T-cell lymphoma

ESH eLearning, Loretta Nastoupil, 403574

Case-based lecture: Mantle cell lymphoma

ESH eLearning, Marie José Kersten, 403573

Case-based Lecture: Adult acute lymphoblastic leukaemia

ESH eLearning, Claire Roddie, 403572

Interactive case: Pediatric acute lymphoblastic leukaemia

ESH eLearning, André Baruchel, 403571

Interactive case: Clinical study opportunities for patients

ESH eLearning, Johannes Waldschmidt, 403570

Case-based lecture: Bispecifics and sequencing in multiple myeloma

ESH eLearning, Monique Minnema, 403569

Case-based lecture: CAR in multiple myeloma

ESH eLearning, María-Victoria Mateos, 403568

Interactive case: CAR-T and infections in multiple myeloma

ESH eLearning, Kai Rejeski, 403567

Interactive case: Follow-up of patients after successful treatment

ESH eLearning, Pere Barba, 403566

Case-based lecture: Alternative cell sources: alloCAR-T, iPSC, NK CAR

ESH eLearning, Stephan Fricke, 403565

Case-based lecture: Bispecific antibodies

ESH eLearning, Martin Hutchings, 403564

Case-based lecture: CAR-T: patient selection and bridging strategies

ESH eLearning, Catherine Thieblemont, 403563

Interactive case: Diffuse large B-cell lymphoma and radiotherapy

ESH eLearning, Tom van Meerten, 403562

CAR T-cell therapy: something old, something new (novel targets/tandem CARs)

ESH eLearning, Jeremy Abramson, 403561

Conference Book (PDF)

ESH eLearning, Faculty / Presenters, 404818

Closing Remarks

ESH eLearning, Jorge Cortes, 404248

Selected Abstract: A predictive scoring system for therapy failure of tyrosine-kinase inhibitors in patients with chronic myeloid leukemia

ESH eLearning, Xiaoshuai ZHANG, 404246

Keynote Presentation: How should we interpret concussions of TKI-stopping studies?

ESH eLearning, Robert Peter GALE, 404245

Hematology service for CML patients in Ukraine: challenges and successes

ESH eLearning, Faculty / Presenters, 404244

Identification and exploitation of the metabolic reprogramming suffered by CML cells that acquire Tyrosine Kinase Inhibitor (TKI) resistance

ESH eLearning, Marta Cascante, 404243

Selected Abstract: The effect of body mass Index on the safety of bosutinib in patients with chronic myeloid leukemia: a post hoc pooled data analysis

ESH eLearning, Susanne Isfort, 404242

Selected Abstract: CML-Registry (CML VI): achievement of ELN treatment milestones is predictive for deep molecular response (DMR) in real-world setting

ESH eLearning, Katharina KOHLBRENNER, 404241

Keynote Presentation: CML: Have we reached the peak?

ESH eLearning, Carlo Gambacorti-Passerini, 404240

Selected Abstract: Why are not all eligible CML patients willing to attempt TKI discontinuation?

ESH eLearning, Daniela Zackova, 404238

Selected Abstract: Sensitive measurement of residual disease in granulocytes and T cells strongly predicts relapse in chronic myeloid leukaemia patients stopping therapy

ESH eLearning, Ilaria S. Pagani, 404237

Keynote Presentation: Are current recommendations enough or too much?

ESH eLearning, Dragana Milojkovic, 404236

From IRIS to SPIRIT toward treatment discontinuation for CML patients

ESH eLearning, François GUILHOT, 404235

Selected Abstract: Tyrosine kinase inhibitor-free remission after salvage therapy for resistance, warning or lack of deep molecular response in chronic myeloid leukemia

ESH eLearning, Delphine Rea, 404234

Selected Abstract: A successful treatment-free remission is achievable also by CML patients lacking optimal requirements

ESH eLearning, Massimiliano BONIFACIO, 404233

Selected Abstract: Treatment free remissions (TFR) in children with chronic myeloid leukemia (CML) - A prospective study from the Tata Memorial Hospital (TMH) pediatric CML (pCML) cohort

ESH eLearning, Nirmalya ROY MOULIK, 404232

Selected Abstract: The European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission

ESH eLearning, Francois-Xavier Mahon, 404231

Keynote Presentation: TFR: How do we move forward?

ESH eLearning, Massimo BRECCIA, 404230

Discussion

ESH eLearning, Faculty / Presenters, 404229

Pro

ESH eLearning, Giuseppe Saglio, 404228

Not yet

ESH eLearning, Jane APPERLEY, 404227

Introduction

ESH eLearning, Pierre LANEUVILLE, 404226

Novel developments in HSC transplant, treatment of GVHD

ESH eLearning, Halvard Boenig, 404225

SATELLITE SYMPOSIUM: How can emerging data further optimise treatment of TKI-resistant CML?

ESH eLearning, Faculty / Presenters, 404224

Selected Abstract: KIR3DL1-HLA-Bw status predict favourable achievement of treatment free remission in CML: results from the POKSTIC trial, a multicentre retrospective observational study

ESH eLearning, Hiroshi Ureshino, 404222

Selected Abstract: BCL-XL a novel biomarker for treatment failure and treatment-free remission in chronic myeloid leukaemia

ESH eLearning, Claire Lucas, 404221

Selected Abstract: The presence of somatic mutations prior to treatment-free remission (TFR) attempt is not associated with TFR failure following tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia patients

ESH eLearning, Dennis KIM, 404219

Keynote Presentation: Hidden signatures: harnessing the full power of biomarkers in chronic myeloid leukaemia

ESH eLearning, S. Tiong ONG, 404218

Clonal hematopoiesis

ESH eLearning, Coleman Lindsley, 404215

CD47 Targeting in myeloid malignancies

ESH eLearning, Ravi Majeti, 404214

The BCL2 family in myeloid malignancies

ESH eLearning, Caroline Heckman, 404213

TP53 mutations in myeloid malignancies

ESH eLearning, Steffen BOETTCHER, 404212

Introductory overview – concepts and challenges

ESH eLearning, Shinya Kimura, 404211

Selected Abstract: Characterization of bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

ESH eLearning, Hong Qian, 404210

Selected Abstract: Overcoming TKI-resistant CML utilizing a novel PROTAC-based BCR::ABL1 degrader

ESH eLearning, Milad Rouhimoghadam, 404209

Selected Abstract: The role of G0/G1 switch gene 2 (G0S2) in lipid metabolism, differentiation, and drug resistance in chronic myeloid leukemia (CML)

ESH eLearning, Anna Eiring, 404208

Keynote Presentation: Resistance to TKI: mutations and beyond

ESH eLearning, Simona SOVERINI, 404207

Germline predisposition to hematopoietic malignancies

ESH eLearning, Lucy Godley, 404206

SATELLITE SYMPOSIUM: Living with CML: How optimizing tolerability can lead to better patient outcomes

ESH eLearning, Faculty / Presenters, 404205

CML is still important and relevant

ESH eLearning, Jerry Radich, 404204

Selected Abstract: Multiomic single-cell characterization of the CD14-CD34+ stem and progenitor cell compartment in chronic myeloid leukemia

ESH eLearning, Hana Komic, 404202

Selected Abstract: SETD2/H3K36mE3 deficiency hinders proper dna damage repair and enhances clonogenic potential of chronic myeloid leukemia (CML) progenitors

ESH eLearning, Manuela Mancini, 404201

Keynote Presentation: The curious case of the leukemic stem cell: why is it so elusive?

ESH eLearning, Ravi Bhatia, 404199

Autophagy networks and cancer pathogenesis

ESH eLearning, Ivan Dikic, 404198

Excellent molecular responses and tolerance observed with frontline asciminib treatment for CP-CML: results from the ALLG CML13 ASCEND-CML study

ESH eLearning, Tim P. Hughes, 404197

Clonal hematopoiesis mutants detected at the time of stopping therapy in deep molecular response are significantly associated with achievement of treatment-free remission (TFR)

ESH eLearning, Susan Branford, 404194

Leukaemia exposure reduces phagocytosis and efferocytosis in Philadelphia negative bone marrow-derived macrophages

ESH eLearning, Martha ZAROU, 404193

Welcome to Mandelieu

ESH eLearning, Jorge Cortes, 404190

Combining daratumumab with CD47 blockade in T-ALL

ESH eLearning, Dennis Schewe, 391225

Precision medicine for T-ALL

ESH eLearning, Guillaume P. Andrieu, 391224

Precision medicine for B-cell precursor ALL

ESH eLearning, Sarah Tasian, 391223

Targeting T-ALL via CCR9

ESH eLearning, Paul Maciocia, 391222

Role of SCT in the era of CAR-T

ESH eLearning, Jae Park, 391221

How to prioritize immune interaction in B-Acute Lymphoblastic Leukemia?

ESH eLearning, André Baruchel, 391220

New antibody-based ALL therapies

ESH eLearning, Federico Lussana, 391219

Front line therapy with inotuzumab ozogamicin

ESH eLearning, Philippe Rousselot, 391218

Comprehensive profiling of leukemia drug sensitivity in pediatric vs adult ALL

ESH eLearning, Jun J. Yang, 391216

Minimal chemotherapy for good-risk childhood ALL

ESH eLearning, Stephen P. Hunger, 391215

Early T-cell precursor (ETP)-ALL

ESH eLearning, Nitin Jain, 391214

The evolution of TKI therapy in Ph+ ALL

ESH eLearning, Nicholas Short, 391211

CDX2 deregulation and UBTF::ATXN7L3 define a novel B-ALL high-risk subtype

ESH eLearning, Marie Passet, 391209

Characterizing relapse initiating cells by single-cell transcriptomics

ESH eLearning, Ronald Stam, 391208

New insights in TLX3 rearranged T-ALL

ESH eLearning, Jules Meijerink, 391207

Adult low-hypodiploid acute lymphoblastic leukemia emerges from preleukemic TP53-mutant clonal hematopoiesis

ESH eLearning, Rathana Kim, 391206

Acute leukaemia of ambiguous lineage

ESH eLearning, Charles Mullighan, 391205

Clinical use of TKIs in Ph-like ALL patients

ESH eLearning, Stephen P. Hunger, 391204

Identifying novel combination therapies for B-ALL harboring the IgH::CRLF2 rearrangement using functional genomics tools

ESH eLearning, Takahiro Maeda, 391203

Menin inhibitors

ESH eLearning, Eytan Stein, 391198

Current therapy for KMT2A-rearranged ALL

ESH eLearning, Janine Stutterheim, 391197

The biology of KMT2A-rearranged leukaemia

ESH eLearning, Katrin Ottersbach, 391196

Conference Book (PDF)

ESH eLearning, Faculty / Presenters, 391194

Panel Discussion

ESH eLearning, Faculty / Presenters, 382687

Case-based lecture: Bone disease in multiple myeloma

ESH eLearning, Elizabeth O’Donnell, 382685

Case-based lecture: Is this myeloma kidney? A case of significantly elevated free serum light chains and kidney failure

ESH eLearning, Fredrik Schjesvold, 382684

Case-based lecture: How I treat amyloidosis

ESH eLearning, Mario Nuvolone, 382683

Interactive case: How I treat Waldenstrom's macroglobulinemia

ESH eLearning, Jorge Castillo, 382682

MM treatment in 2030

ESH eLearning, Kenneth C. Anderson, 382681

Panel Discussion

ESH eLearning, Faculty / Presenters, 382680